GSK Gains Foothold In U.S. Skin Care With Stiefel Deal
This article was originally published in The Rose Sheet
Executive Summary
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion with the acquisition of Stiefel Laboratories, a move that provides GSK a foothold in the U.S. market for nonprescription skin-care products
You may also be interested in...
Dermatology Among Emerging Rx-To-OTC Switch Categories
FDA threw the switch floodgates open with the Nonprescription Safe Use Regulatory Expansion (NSURE) initiative and has fueled interest with recent first-in-class switches of Nasacort and Oxytrol for Women. Experts say likely categories for successful switches include dermatology, as drugs for treating eczema, acne and other skin conditions typically do not have systemic effects and address ailments that are readily recognized and understood by consumers.
Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives
GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.
Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives
GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.